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Introduction: Radiation treatment has been associated with radiation induced cardiotoxicity, 
especially with older, long-outdated, techniques. Such complications include pericarditis, 
myocardial ﬁ  brosis, valvular injury, ischemic heart disease, and myocardial infarction.
Aim: To assess the effect of outdated breast radiation therapy (RT) – using a diagnostic 
CT scanner in the absence of a CT simulator – on cardiac function in women with stage II left 
breast cancer.
Patients and Methods: Sixty-two women under 65 with stage II left breast cancer who received 
post-operative RT using a diagnostic computed tomography scanner were studied between 1997 
and 2001. Participants underwent a clinical interview, ECG, and echocardiography before and 
6 months and 5 years after RT.
Results: There was no serious cardiotoxicity at 6 months and 5 years after radiotherapy. 
A 23% increase in hypertensive patients, and a slight decrease (2.3%) in ejection fraction was 
observed after 5 years, with 3 patients (5%) developing abnormalities. Two patients presented 
abnormal electrocardiographic ﬁ  ndings within 6 months of RT.
Conclusion: Our study showed that RT for left breast cancer was not associated with signiﬁ  cant 
alteration in heart morbidity or mortality within 5 years of treatment, despite the lack of a 
simulator.
Keywords: radiotherapy, breast cancer, cardiotoxicity, acute myocardial infraction, ischemic 
heart disease
Introduction
Adjuvant radiation therapy (RT) in patients with early breast cancer signiﬁ  cantly 
reduces locoregional recurrence in up to 60% of cases (Gyenes 1998). The most recent 
systematic overview, conducted by the Early Breast Cancer Trialists Collaborative 
Group (EBCTCG), indicated that post-mastectomy RT reduces absolute breast cancer 
mortality by an average of 5% at 10 years (EBCTCG 2000). The relative beneﬁ  ts are 
similar after mastectomy or breast conservation surgery in the presence or absence 
of adjuvant systemic therapies as well as in axillary node-negative and -positive 
patients.
However, RT has been associated with radiation-induced cardiotoxicity, especially 
with older, long-outdated, techniques (Gyenes 1998; Carlson et al 1991; Cutuli 2000). 
Such complications include pericarditis, myocardial ﬁ  brosis, valvular injury, ischemic 
heart disease, and myocardial infarction, and have been observed particularly in 
the literature on photon radiation of post-mastectomy chest-wall and direct internal 
mammary lymph nodes (Rutqvist et al 1992; Gyenes et al 1994). A meta-analysis 
by Cuzick (2005) showed a 62% increase in cardiac death in women receiving RT. 
Similarly, EBCTCG found a 30% increase in vascular mortality in women receiving RT Therapeutics and Clinical Risk Management 2008:4(6) 1360
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for breast cancer (Clarke et al 2005). Some authors reported 
no increased risk for patients with left breast disease treated 
with techniques used approximately since 1975 (Hojris et al 
1999; Rutqvist et al 1998), while others claimed a 2-fold 
risk of fatal myocardial infarction for left-sided treatment 
compared with right-sided (Paszat et al 1998).
At present, there is a controversy as to whether modern 
RT techniques are also cardiotoxic, especially in cases 
of left breast cancer. Gustavsson et al (1999) found that 
women younger than 50 years at the time of adjuvant RT 
following mastectomy for early breast cancer had no serious 
cardiac sequelae 13 years on. On the contrary, Paszat et al 
(1998) suggested that adjuvant RT for left-sided breast 
cancer diagnosed in women younger than 60 is associ-
ated with a higher risk of fatal myocardial infarction 10 to 
15 years later compared with adjuvant RT for right-sided 
cases. Moreover, Harris et al (2006) proposed that irradia-
tion to the left breast is not associated with a higher risk of 
cardiac death up to 20 years after treatment, but is associ-
ated with an increased rate of diagnoses of coronary artery 
disease and myocardial infarction compared with right 
breast treatment.
The aim of our study is to assess the effect of outdated 
breast RT – using a diagnostic CT scanner in the absence 
of a computed tomography (CT) simulator – on cardiac 
function in women with stage II left breast cancer, using 
non invasive techniques such as electrocardiogram (ECG) 
and echocardiography.
Patients and methods
We studied 62 women younger than 65 years with stage II 
left breast cancer between 1997 and 2001, who received 
post-operative RT in the department of Radiation Oncology 
in AHEPA University Hospital, Thessaloniki, Greece. None 
of them underwent radical mastectomy before RT. At the 
time of diagnosis, all patients were younger than 65 years 
(mean age 56 years, range 48–64).
Participants underwent clinical interview, ECG, and 
echocardiography before and 6 months and 5 years after RT. 
Patients with ECG abnormalities, previous cardiovascular 
disease, or echocardiographic abnormalities were excluded 
from the study. Thyroid stimulating hormone (TSH) was 
measured in all patients before and after RT to establish that 
they were all euthyroidic.
Using echocardiography, LVIDd (left ventricular 
internal dimension in diastole), LVIDs (left ventricular 
internal dimension in systole), IVSd (interventricular septum 
in diastole), IVSs (interventricular septum in systole), 
EDV (end diastolic volume), ESV (end systolic volume), 
EF (ejection fraction) as well as the presence of pericardial 
ﬂ  uid was assessed.
Radiotherapy technique
Accurate patient-speciﬁ  c anatomic information of the breast 
is a prerequisite for planning and implementing the delivery 
of radiation to the entire breast while minimising exposure 
to critical structures such as lungs, ribs and heart. In our 
department, conventional or CT simulators were unavailable, 
so the image data from the patients’ breasts were taken by 
a diagnostic multi-slice spiral CT scanner with a ﬂ  at couch 
and a gantry opening 80 cm in diameter, which could be 
restrictive for setting up patients with immobilization devices 
in the treatment position.
During RT all patients were placed supine with both 
hands up and behind their head in a precise reproducible 
position of treatment. The anterior and lateral isometric lines 
and other landmarks were marked on the patients’ skin by 
radiopaque markers or lead beads.
From all diagnostic CT slices, the central one was 
chosen as the one in where the disease was most extensive. 
Thereafter, we delineated the target area as well as the 
organs at risk, and these data were input to a 2-dimensional 
(2D) computer treatment planning. The entire breast was 
included in the planning target volume (PTV) with a 1 cm 
margin around palpable breast tissue. The physician and 
the radiotherapist could then select the treatment beam 
directions. The objective was to treat the PTV disease tissue 
plus a 1 cm margin to a tumoricidal dose while limiting the 
dose to the surrounding normal tissues. If critical tissues 
were located nearby, the aim was to keep the dose to these 
organs to a level within the acceptable limit of complication. 
The reference point (100% dose) was located in the centre 
of the PTV and in the junction of the axes of the tangential 
ﬁ  elds. The dose variation permitted inside the PTV was 
between –5% and +10%. In order to further adjust doses 
and to prevent radiation of sensitive healthy tissues such 
as lungs and pericardium, axes with a deviation larger than 
180o as well as wedges of different angles (15o, 30o, 45o, 
60o) were employed.
Radiotherapy was delivered with a Cobalt-60 1.25 MV 
treatment unit using a pair of opposed tangential beams 
(medial and lateral). The daily dose was 200 cGy, the total 
dose on the PTV was 50 Gy in 25 fractions over 5 weeks 
without boost, while in some patients a boost dose of 5 to 
6 Gy was given as necessary. None underwent RT to the 
internal mammary chain.Therapeutics and Clinical Risk Management 2008:4(6) 1361
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Results
Table 1 summarizes the clinical symptoms as well as ECG 
and echocardiographic ﬁ  ndings in our patients before and 
6 months and 5 years after RT. SPSS 11.0 has been used for 
the statistical analysis of data.
No patient developed angina pectoris or other manifesta-
tions of coronary heart disease at 6 months or 5 years after 
RT. However, there was a 23% increase in hypertensive 
patients within a period of 5 years after RT.
Only 2 patients showed ECG abnormalities within 
6 months of RT (ST depression and right bundle bunch block 
respectively). Conversely, there were only 3 patients who devel-
oped QRS and/or ST abnormalities within 5 years of RT.
Pericardial ﬂ  uid was present in only 1 patient at 6 months 
after RT. However, this ﬁ  nding was not permanent, since it 
did not reappear at 5 years after RT.
There was a slight decrease (2.3%) in EF within 5 years 
after RT. However, there was no signiﬁ  cant change in the 
other echocardiographic parameters included in our study.
Thyroid function could not be evaluated due to lack of data 
for 27 patients. The other 35 patients remained euthyroidic.
Discussion
This study was undertaken under difﬁ  cult circumstances 
because modern technologies such as a conventional simulator 
or a CT, connected online to a 3D computerized treatment 
planning, were not available in our department. Instead, we 
tried to substitute for the lack of a CT simulator by using a 
diagnostic CT scanner, which was the closest equivalent to a 
simulator. However, many of the advantages of a conventional 
simulator were lacking, and only one slice could be input to 
the 2D computerized treatment planning, so planning and mea-
suring the given dose according to the heart volume were not 
possible. Another disadvantage was that no correlation existed 
between the incidence of cardiac sequela in the women of our 
study and that of women irradiated on the right breast.
Reported data from studies on the comprehensive exami-
nation of the long-term cardiac mortality and morbidity after 
left breast irradiation using contemporary RT techniques 
indicate a signiﬁ  cant association with an increased inci-
dence of coronary artery disease and myocardial infraction 
20 years after RT treatment. However, our study shows only 
a 23% increase in hypertensive patients 5 years after RT. 
Furthermore, none of the patients developed myocardial 
infraction or coronary artery disease. Also, the slight decrease 
in EF may be attributed to the aging of the patients, rather 
than the long-term effect of RT. All other echocardiographic 
parameters remained practically unchanged, showing that 
RT did not affect them. Pericardial ﬂ  uid was present in only 
1 case at 6 months after RT, an effect that was temporary.
Table 1 Clinical manifestations, ECG changes, and echocardiographic parameters 6 months before and 5 years after radiotherapy for 
left breast cancer
Before RT (n = 62) Six months after RT (n = 62) Five years after RT (n = 62)
Clinical symptoms
 Angina 0 0 0
 Hypertension 24 25 31 (p  0.05)
ECG changes
  QRS and/or ST changes 0 1 3
  Other ECG changes 0 1 2
Echocardiographic ﬁ  ndings
 Pericardial  ﬂ  uid 0 1 0
 EDV  (mL) 111.5 ± 17.9 112.5 ± 13.7 117.5 ± 17.1
 ESV  (mL) 43.8 ± 7.5 43.9 ± 8.4 45.8 ± 9.5
 EF  (%) 65.7 ± 7.9 65.3 ± 6.8 63.4 ± 7.1
 LVIDd  (cm) 5.1 ± 0.4 5.2 ± 0.8 5.4 ± 0.5
 LVIDs  (cm) 3.7 ± 0.7 3.8 ± 0.9 3.9 ± 0.6
 LVPwd  (cm) 0.71 ± 0.2 0.72 ± 0.2 0.74 ± 0.1
 IVSd  (cm) 0.75 ± 0.3 0.76 ± 0.1 0.79 ± 0.1
 IVSs  (cm) 1.01 ± 0.2 1.02 ± 0.3 1.04 ± 0.2
Abbreviations: EDV, end diastolic volume; ESV, end systolic volume; EF, ejection fraction; LVIDd, left ventricular internal dimension in diastole; LVIDs, left ventricular internal 
dimension in systole; IVSd, interventricular septum in diastole; IVSs, interventricular septum in systole.Therapeutics and Clinical Risk Management 2008:4(6) 1362
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These results contrast with those in most other publications. 
In the most recent population-based case-cohort study (Paszat 
et al 2007), the authors concluded that in addition to risk factors 
such as increasing age at diagnosis, smoking history, and his-
tory of acute myocardial infarction before post-operative RT, 
anatomic characteristics of RT such as RT for left-sided tumors, 
the use of an anterior internal mammary ﬁ  eld, and increased area 
of an anterior left breast boost ﬁ  eld are associated with increased 
risk of acute myocardial infarction (Paszat et al 2007).
The discrepancy could most likely be explained by 
the small total number of participants, the short follow-up 
period, the absence of internal mammary irradiation, and, 
especially, the younger mean age of patients at the time of 
diagnosis (56 years).
To conclude, our study showed that RT for left breast 
cancer was not associated with signiﬁ  cant alteration in heart 
morbidity and mortality within 5 years of treatment despite 
the lack of a simulator. However, a 20-year follow-up of these 
patients and a comparison with work that includes the same 
methods of treatment and RT techniques for the right breast 
would be helpful in order to better evaluate our results.
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